文献速递骨软组织肉瘤与黑色素瘤

首创微生物生态系统治疗4(MET4)联合免疫检查点抑制剂治疗晚期实体瘤患者(MET4-IO试验)

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial).
PubMed 文献 · Ann Oncol · 2023-03-01

MET4-IO是一项早期临床试验,评估口服30种菌种微生物联合体MET4联合免疫检查点抑制剂(ICI)治疗晚期实体瘤的安全性、耐受性和生态学反应。试验达到主要安全性和耐受性终点,主要生态学终点无统计学显著差异,但随机化后MET4菌种相对丰度出现因患者和菌种而异的差异,部分与ICI应答相关的菌属(如肠球菌属和双歧杆菌属)相对丰度增加,MET4定植与血浆和粪便初级胆汁酸降低相关。

要点

  • MET4联合ICI在晚期实体瘤中达到主要安全性和耐受性终点。
  • 主要生态学终点无统计学显著差异,但MET4菌种相对丰度变化因患者和菌种而异。
  • 肠球菌属和双歧杆菌属等与ICI应答相关菌属相对丰度增加,MET4定植与初级胆汁酸降低相关。

核心结论

  • 本试验首次报告在接受ICI的晚期癌症患者中使用微生物联合体作为粪菌移植(FMT)的替代方案,结果支持进一步开发微生物联合体作为ICI治疗的辅助干预。

研究设计与样本

  • 早期临床试验,评估口服30种菌种微生物联合体MET4联合ICI治疗晚期实体瘤患者的安全性、耐受性和生态学反应。

主要发现

  • 试验达到主要安全性和耐受性终点。
  • 主要生态学终点无统计学显著差异。
  • 随机化后MET4菌种相对丰度出现因患者和菌种而异的差异。
  • 包括肠球菌属和双歧杆菌属在内的一些MET4菌属相对丰度增加,这些菌属先前与ICI应答相关。
  • MET4定植与血浆和粪便初级胆汁酸降低相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The intestinal microbiome has been associated with response to immune checkpoint inhibitors (ICIs) in humans and causally implicated in ICI responsiveness in animal models. Two recent human trials demonstrated that fecal microbiota transplant (FMT) from ICI responders can rescue ICI responses in refractory melanoma, but FMT has specific limitations to scaled use. PATIENTS AND METHODS: We conducted an early-phase clinical trial of a cultivated, orally delivered 30-species microbial consortium (Microbial Ecosystem Therapeutic 4, MET4) designed for co-administration with ICIs as an alternative to FMT and assessed safety, tolerability and ecological responses in patients with advanced solid tumors. RESULTS: The trial achieved its primary safety and tolerability outcomes. There were no statistically significant differences in the primary ecological outcomes; however, differences in MET4 species relative abundance were evident after randomization that varied by patient and species. Increases in the relative abundance of several MET4 taxa, including Enterococcus and Bifidobacterium, taxa previously associated with ICI responsiveness, were observed and MET4 engraftment was associated with decreases in plasma and stool primary bile acids. CONCLUSIONS: This trial is the first report of the use of a microbial consortium as an alternative to FMT in advanced cancer patients receiving ICI and the results justify the further development of microbial consortia as a therapeutic co-intervention for ICI treatment in cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Spreafico A, Heirali AA, Araujo DV, et al. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann Oncol. 2023. PMID: 36863483. doi:10.1016/j.annonc.2023.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。